9 ফলাফল
FIELD OF THE lNVENTION
The present invention is concerned with anti-cancer therapies which utilize selective DNA polymerase substrate analogues as the basis for treatment and is directed to specific means for selectively employing the activity of terminal deoxynucleotidyl transferase, the unique DNA
FIELD OF THE INVENTION
The present invention relates to pharmaceuticals that affect cell adhesion, inhibit cancer cell metastasis, and induce apoptosis both in vitro and in vivo.
Background of the Invention
Cell adhesion is one important property that differentiates multi-cellular organisms from
The present invention relates to a pharmaceutical which comprises a compound of the formula
##STR00001##
where R.sub.1, independent of each other, is an unbranched or branched, saturated, singly or multiply unsaturated, optionally substituted C.sub.11-C.sub.21 alkyl, alkylene or alkynyl radical,
The present invention relates to a pharmaceutical which comprises a compound of the formula
##STR00002## where R.sub.1, independent of each other, is an unbranched or branched, saturated, singly or multiply unsaturated, optionally substituted C.sub.11-C.sub.21 alkyl, alkylene or alkynyl radical,
The present invention relates to a pharmaceutical which comprises a compound of the formula
##STR00001## where R.sub.1, independent of each other, is an unbranched or branched, saturated, singly or multiply unsaturated, optionally substituted C.sub.11-C.sub.21 alkyl, alkylene or alkynyl radical,
BACKGROUND OF THE INVENTION
This invention relates to novel nitrosourea compounds which possess a high level of inhibitory activity against leukemia and tumors with a low toxicity and which are therefore useful in the therapeutic treatments of leukemia and tumors. This invention further relates to a
TECHNICAL FIELD
The present invention relates to a marker for use in determination of the sensitivity of a cancer patient to an anti-cancer agent, which marker can determine whether or not the cancer of the patient has a therapeutic response to the anti-cancer agent, and to application of the
TECHNICAL FIELD
The present invention relates to a marker for use in determination of the sensitivity of a cancer patient to an anti-cancer agent to be administered thereto, which marker can determine whether or not the cancer of the patient has a therapeutic response to the anti-cancer agent, and
This application is a National Stage of PCT/JP13/054488 filed Feb. 22, 2013 and claims the benefit of JP 2012-037448 filed Feb. 23, 2012.
TECHNICAL FIELD
The present invention relates to a marker for use in determination of the sensitivity of a cancer patient to an anti-cancer agent to be